Drug Profile
Tadalafil oral film - IntelGenx
Alternative Names: EXORDIA; INT-007; INT0007; INT0007/2006; Tadalafil - IntelGenx; Tadalafil film - IntelGenxLatest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator IntelGenx Corp.
- Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Gastrokinetics; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Pyridones; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Erectile dysfunction
Most Recent Events
- 28 Apr 2023 Preregistration for Erectile dysfunction (In volunteers) in USA (PO) (IntelGenx website, April 2023)
- 10 Nov 2020 IntelGenx has patent protection for tadalafil in USA
- 28 Oct 2020 No recent reports of development identified for phase-I development in Erectile-dysfunction(In volunteers) in USA (PO, Film)